Participants 49 115 5
predominantly classic neovascular age-related macular degeneration
Participants 308 401 3
Predominantly Classic Choroidal Neovascularization [CNV] in Age-Related Macular Degeneration)
Participants 490 590 7
423 patients received ranibizumab (0.3 or 0.5 mg) monthly + sham PDT or PDT + monthly sham injection
